IORT reimbursement unchanged; payment values
for alternative, longer courses of radiation therapy reduced


NASHUA, N.H. – September 20, 2020 – iCAD, Inc. (NASDAQ:
ICAD), a global medical technology leader providing innovative cancer detection
and therapy solutions, is providing additional comments following the Centers
for Medicare & Medicaid Services’ (CMS) publication of a new Innovation
Center model designed, according to CMS, to improve the quality of care for
cancer patients receiving radiotherapy and reduce Medicare expenditures through
bundled payments. CMS indicated that the new Radiation Oncology (RO) Model
allows this focus on value-based care by creating simpler, more predictable
payments that incentivize cost-efficient and clinically effective treatments to
improve quality and outcomes. The RO Model, part of a final rule on specialty
care models issued by CMS, is scheduled to be implemented on January 1, 2021.

The RO Model is intended to address payment differences and
provide bundled payments during a 90-day episode of care to participating radiotherapy
providers and suppliers furnishing radiotherapy for 16 different cancer types,
including anal cancer, brain metastases, breast cancer, cervical cancer,
colorectal cancer and prostate cancer.

The notice sets forth Medicare’s national base payment rates
for the radiation oncology services subject to the new payment model that are
provided during 90-day episodes of care, regardless of the treatment modality

Under Medicare’s traditional fee-for-service payment system,
the estimated reimbursement using Medicare’s 2020 national rates for treatment
of breast cancer include the following:

  • For intensity modulated radiation therapy
    (IMRT), payment values are approximately $3,147 for physicians and $23,213 for
  • For external beam radiation therapy (EBRT),
    payment values are approximately $3,349 for physicians and $13,445 for
  • For Xoft intraoperative radiation therapy
    (IORT), payment values are approximately $402 for physicians and $7,942 for

In 2021 the estimated reimbursement for the selected 30% of
the country will include the following:

  • For selected modalities (including IMRT and
    EBRT) under the RO Alternative Payment Model, payment values will be
    approximately $2,081 for physicians and $10,129 for facilities.[iv]

The Medicare proposed reimbursement for Xoft, which would
apply to 100% of the market and is subject to final CMS approval, is $360 for
physicians and $7,938 for facilities.


If implemented as scheduled, the RO Model will require
participation from radiotherapy providers and suppliers that furnish
radiotherapy services within selected geographic areas that contain
approximately 30 percent of all eligible Medicare fee-for-service radiotherapy
episodes nationally.

Individual provider reimbursement rates, including all of
those referenced above, will vary based on a number of factors, including
adjustments for each participant’s case-mix, historical experience, and
geographic location. Such variations may be significant. CMS further adjusts
payment amounts by applying a discount factor. Accordingly, the above
reimbursement rates, while based on CMS Final Rules and related guidelines,
should be considered estimates for illustration.

“The Xoft System continues to offer a proven-effective,
high-quality treatment option that offers the flexibility to treat cancer
anywhere in the body, with added mobility, cost and treatment time advantages.
This technology allows patients who are candidates to replace weeks of daily
radiation treatments with just one targeted dose of radiation, delivered at the
time of surgery – which is particularly critical during the era of COVID-19, as
it could contribute to a reduction in the healthcare system resources needed
for breast cancer patients and reduce those patients’ risk of exposure to the
novel coronavirus by minimizing the number of visits required to a hospital or
medical facility.”

In the final notice, CMS did not include IORT treatments
(including CPT codes 77424 and 77425) within the new alternative payment model
for radiation oncology. As a result, whether or not a particular physician
practice or hospital is subject to the new radiation oncology payment model,
IORT services covered by Medicare will continue to be subject to the existing
payment systems for physician services and hospital outpatient
services. CMS recently issued proposed payment rates for the Medicare
physician fee schedule and Medicare’s hospital outpatient prospective payment
system under its annual rulemaking process, and most observers anticipate that
CMS will post the final notices with 2021 rates for these payment systems on or
around December 1, 2020. 

“A growing body of evidence continues to support IORT,
including the recent publication of long-term data that showed IORT was as
effective as traditional EBRT,[v]
added Klein. “Regardless of this final decision, IORT with the Xoft System
still delivers on the triple aim goal, benefitting patients, clinicians, and
payers alike. iCAD intends to collaborate with advocacy groups and other
members of the breast cancer community, along with CMS and Congressional
leadership, to ensure that women throughout the U.S., including individuals in
underserved, rural and urban communities, increasingly have access to the best
clinical options for treating breast cancer including technologies such as
Xoft’s single-fraction therapy option.”


iCAD, Inc.


in Nashua, NH, iCAD is a global medical technology
leader providing innovative cancer detection and therapy solutions.


The Xoft® Axxent® Electronic
Brachytherapy (eBx®) System® is FDA-cleared, CE marked and licensed in a
growing number of countries for the treatment of cancer anywhere in the body.
It uses a proprietary miniaturized x-ray source to deliver a precise,
concentrated dose of radiation directly to the tumor site, while minimizing
risk of damage to healthy tissue in nearby areas of the body.


For more information, visit and


Forward-Looking Statements


Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995, including statements about the future prospects
for the Company’s technology platforms and products. Such forward-looking
statements involve a number of known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or achievements of the
Company to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Such
factors include, but are not limited, to the Company’s ability to achieve
business and strategic objectives, the ability of IORT to provide flexibility,
mobility or other advantages, to be more beneficial for patients than traditional
therapy or to be accepted by patients or clinicians, the impact of supply and
manufacturing constraints or difficulties, product market acceptance, possible
technological obsolescence of products, increased competition, litigation
and/or government regulation, changes in Medicare or other reimbursement
policies, risks relating to our existing and future debt obligations,
competitive factors, the effects of a decline in the economy or markets served
by the Company; and other risks detailed in the Company’s filings with the
Securities and Exchange Commission. The words “believe,” “demonstrate,”
“intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,”
“seek,” and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under no
obligation to provide any updates to any information contained in this release.
For additional disclosure regarding these and other risks faced by iCAD, please
see the disclosure contained in our public filings with the Securities and
Exchange Commission, available on the Investors section of our website at and on the SEC’s website at


Media inquiries:

Jessica Burns, iCAD  



Amy Cook, iCAD


Investor Relations:

Jeremy Feffer,
LifeSci Advisors



A representative scenario involving fee for service billing for 35 fractions of
IMRT using final PFS and HOPPS rates (CMS-1715-F and CMS-1717-F) including
HCPCS codes: 77263 (1 unit), 77301 (1 unit), 77417 (1 unit), 77334 (5 units),
77336 (7 units), 77385/G6015 (35 units), 77387/G6002 (35 units), 77427 (7
units), 77470 (1 unit)

A representative scenario involving fee for service billing for 35 fractions of
EBRT using final PFS and HOPPS rates (CMS-1715-F and CMS-1717-F) including
HCPCS codes: 77263 (1 unit), 77280 (7 units), 77290 (1 unit), 77300 (7 units),
77417 (7 units), 77331 (3 units), 77334 (5 units), 77336 (7 units), 77387/G6002
(35 units), 77412/G6012 (35 units), 77427 (7 units)

A representative scenario involving fee for service billing for 1 fraction of
eBx IORT using final PFS and HOPPS rates (CMS-1715-F and CMS-1717-F): 77469 (1
unit), 77261 (1 unit)

CMS-5527-F, Specialty Care Models to Improve Quality of Care and Reduce

Vaidya, JS et al. (2020). Long term survival and local control outcomes from
single dose targeted intraoperative radiotherapy during lumpectomy
(TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ 2020;370:m2836
Accessed via